BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Tyrx presents early clinical results from AIGISRXTM antibacterial envelope retrospective registry
News | 05. 14. 2009
TYRX
TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices announced today at the 30th Annual Scientific Sessions of the Heart Rhythm Society the initial, interim clinical results from its AIGISRXTM Antibacterial Envelope Retrospective Registry.
